Skip to main
RGEN

Repligen (RGEN) Stock Forecast & Price Target

Repligen (RGEN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Repligen demonstrated significant growth in its revenue streams, with CDMO and biopharmaceutical revenues increasing over 20% year-over-year, while consumables and capital equipment revenues also saw similar growth. The company raised its full-year 2025 revenue guidance to a range of $715-735 million, up from a previous estimate of $695-720 million, reflecting an optimistic outlook for future performance. Notably, Repligen also reported double-digit revenue and order volume increases across all product categories, indicating robust demand and a strong position within the bioprocessing market.

Bears say

Repligen has lowered its forecast for 2025 adjusted operating margin and adjusted EBITDA margin, indicating potential challenges in maintaining profitability. The company faces risks associated with product technology reliability and customer orders, which could lead to lost revenue, delayed market acceptance, and increased costs, ultimately impacting its financial performance. Additionally, despite a solid performance in certain areas, any decline in large customer orders poses a significant threat to Repligen’s revenues and overall financial condition.

Repligen (RGEN) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Repligen (RGEN) Forecast

Analysts have given Repligen (RGEN) a Buy based on their latest research and market trends.

According to 10 analysts, Repligen (RGEN) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $174.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $174.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Repligen (RGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.